Earnings ·
Profound Medical Corp. reported financial results for the quarter ended June 30, 2026, recording total revenue of…
PROFProfound Medical Corp.
Profound Medical Corp. reported financial results for the quarter ended June 30, 2026, recording total revenue of approximately $2.5 million, a 12% year-over-year increase. This figure excludes approximately $3.1 million in TULSA product shipments delayed from late June into July due to logistics issues; excluding this timing difference, revenue would have grown 153%. Gross margin expanded to 78%, and operating expenses declined 16% to $13.0 million, resulting in a net loss of $9.5 million ($0.26 per share), a 39% improvement from the prior year period. The company received over $7.0 million in new purchase orders during the quarter and announced that Johns Hopkins and Prime Healthcare employee health plans now cover the TULSA Procedure. Profound reiterated its full-year 2026 revenue guidance of approximately $25.0 million. Profound Medical Corp. is a commercial-stage medical device company developing and marketing interventional MRI procedures for prostate and other conditions.